Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Randomized, Double-Blind, Multicenter phase II trial comparing the efficacy of chemotherapy with cisplatin and gemcitabine plus sorafenib (BAY 43-9006) versus gemcitabine plus cisplatin, and placebo in the treatment of locally advanced Respectively. Metastatic urothelial AB 31/05 - RUTTE 204 - SUSE.

Trial Profile

Prospective, Randomized, Double-Blind, Multicenter phase II trial comparing the efficacy of chemotherapy with cisplatin and gemcitabine plus sorafenib (BAY 43-9006) versus gemcitabine plus cisplatin, and placebo in the treatment of locally advanced Respectively. Metastatic urothelial AB 31/05 - RUTTE 204 - SUSE.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary) ; Cisplatin; Gemcitabine
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2012 Company (Bayer HealthCare) added as trial sponsor/affiliate as reported by German Clinical Trials Register record.
    • 15 Feb 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003397).
    • 07 Sep 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top